AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-53. (Canceled)

54. (New) A method of inhibiting rejection of grafted cells, tissue, or organ in a mammal in need thereof comprising administering to the mammal a dose, effective to inhibit graft rejection, of a composition comprising purified complexes, each complex consisting essentially of a heat shock protein non-covalently bound to a peptide, wherein the peptide is not an alloantigen of the grafted cells, tissue, or organ, wherein the heat shock protein is a member of the hsp90 family of heat shock proteins, and wherein the composition is administered after the cells, tissue, or organ is grafted to the mammal.

55. (New) A method of inhibiting rejection of grafted cells, tissue, or organ in a mammal in need thereof comprising administering to the mammal a dose, effective to inhibit graft rejection, of a composition comprising purified complexes, each complex consisting essentially of a heat shock protein non-covalently bound to a peptide, wherein the peptide is not an alloantigen of the grafted cells, tissue, or organ, and wherein the heat shock protein is a member of the hsp90 family of heat shock proteins, the method further comprising administering to the mammal a sample of cells or tissue obtained from the cells, tissue, or organ donor prior to administration of the composition, and wherein said composition is administered prior to the cells, tissue, or organ being grafted to the mammal.

56. (New) The method of claim 54 or 55, wherein the amount of the complexes present in the composition is 100 μg or more.

57. (New) The method of claim 54 or 55, wherein the complexes are isolated from a healthy organ of the mammal, wherein said mammal is not experiencing graft rejection or an autoimmune response directed at said healthy organ.

58. (New) The method of claim 54 or 55, wherein the heat shock protein is not an alloantigen of the grafted cells, tissue, or organ.

59. (New) The method of claim 54 or 55, wherein the grafted cells, tissue, or organ is skin, liver, kidney, heart, bone marrow, pancreas, lung, cornea, cartilage, or cells derived therefrom.

60. (New) The method of claim 59, wherein the grafted cells or tissue is skin or cells derived from skin.

61. (New) The method of claim 54 or 55, wherein the heat shock protein is a mammalian heat shock protein.

62. (New) The method of claim 54 or 55, wherein the heat shock protein is human heat shock protein.

63. (New) The method of claim 54 or 55, wherein the heat shock protein is gp96.

64. (New) The method of claim 54 or 55, wherein the heat shock protein is hsp90.

65. (New) The method of claim 54 or 55, wherein the heat shock proteins of said complexes are a combination of gp96 and hsp90.

66. (New) The method of claim 54 or 55, wherein the mammal is human.

67. (New) The method of claim 58, wherein the mammal is human.

68. (New) The method of claim 63, wherein the mammal is human.

69. (New) The method of claim 54 or 55, wherein said composition comprises a purified population of complexes, each complex in said population consisting essentially of a heat shock protein non-covalently bound to a peptide, and wherein said population of complexes comprises different peptides.

70. (New) The method of claim 56, wherein the heat shock protein is gp96.

71. (New) The method of claim 56, wherein the mammal is human.